Integrated sentinel surveillance of influenza and SARS-CoV-2 and the development of the Global Influenza Surveillance and Response System Plus

Virtual meeting
12 – 14 October 2021
## Contents

Acknowledgements ......................................................................................................................... iv
Acronyms ........................................................................................................................................ iv
Background ....................................................................................................................................... 1
Objectives of the meeting ................................................................................................................ 1
Meeting overview .......................................................................................................................... 2
Impact of the COVID-19 pandemic on influenza sentinel surveillance ....................................... 2
The need for integrated respiratory sentinel surveillance ............................................................ 2
Integrated surveillance guidelines .................................................................................................. 3
GISRS Plus ......................................................................................................................................... 5
Conclusions and next steps ............................................................................................................. 6
References ......................................................................................................................................... 6
Annex 1. Meeting agenda .................................................................................................................. 8
Annex 2. List of participants ............................................................................................................. 12
Annex 3. Declarations of interest .................................................................................................... 17
Acknowledgements

The World Health Organization (WHO) acknowledges the experts and countries who participated in the WHO consultation on integrated sentinel surveillance of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the development of the Global Influenza Surveillance and Response System Plus: virtual meeting. Thanks are due to the chair, Rahman Mahmudur, and co-chairs, Cheryl Cohen and Maria Zambon, and to Harry Campbell who served as rapporteur of the meeting.

Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARI</td>
<td>Acute respiratory infection</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>EQAP</td>
<td>External quality assessment project</td>
</tr>
<tr>
<td>GISRS</td>
<td>Global Influenza Surveillance and Response System</td>
</tr>
<tr>
<td>GISAID</td>
<td>Global Initiative on Sharing All Influenza Data</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza-like illness</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>NIC</td>
<td>National Influenza Centre</td>
</tr>
<tr>
<td>PISA</td>
<td>Pandemic influenza severity assessment</td>
</tr>
<tr>
<td>SARI</td>
<td>Severe acute respiratory infection</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe acute respiratory syndrome coronavirus 2</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Background

The first WHO consultation from 6-8 October 2020 developed interim guidance for the integrated epidemiological and laboratory surveillance of influenza and SARS-CoV-2 using the Global Influenza Surveillance and Response System (GISRS) and associated systems. Since the implementation of the interim guidance, including expediting GISRS genomic surveillance as part of global efforts, extensive experience has been gained at national, regional and global levels. Meanwhile, the approach of integrated surveillance of influenza and SARS-CoV-2 to simultaneously address critical public health needs of both influenza and SARS-CoV-2 using existing systems has been welcomed by countries and supported by international agencies.

A year and a half into the coronavirus disease 2019 (COVID-19) pandemic, countries and the world have started building longer-term health emergency preparedness. The low seasonal influenza activity and frequent detections of zoonotic influenza infections are an ominous sign of an impending threat of influenza. It was critical to have a follow up global consultation one year after the first consultation to review and address immediate needs and discuss strategy for the mid- to long-term development of GISRS. A virtual consultation was, therefore, held on 12-14 October 2021. An agenda and list of participants is provided in the meeting report annex.

Objectives of the meeting

The overall aim was to update the interim guidance on the integrated surveillance of influenza and SARS-CoV-2 and chart a roadmap for the development of GISRS towards GISRS Plus for influenza and other respiratory viruses including SARS-CoV-2, respiratory syncytial virus and other future respiratory viruses of pandemic and epidemic potential. Specific meeting objectives were to:

- take stock of experience and lessons learned from countries in using influenza sentinel systems in sampling, testing, sequencing, reporting SARS-CoV-2 surveillance data and sharing of SARS-CoV-2 genetic sequence data
- review and update the interim guidance on integrating influenza and SARS-CoV-2 surveillance
- assess and update existing surveillance tools for influenza as learned from the COVID-19 pandemic to date, and potentially for SARS-CoV-2
- review and enhance readiness of the GISRS pandemic response
- develop a roadmap for GISRS development towards GISRS Plus.

Expected meeting outcomes were updated practical guidance on integrated surveillance of influenza and SARS-CoV-2; a compendium of country best practices for integrating influenza and SARS-CoV-2 sentinel surveillance; and a GISRS Pandemic Response Plan and a GISRS Plus roadmap.
Meeting overview

The meeting reviewed recent evidence on severe acute respiratory infection (SARI), influenza-like illness (ILI) and acute respiratory infection (ARI) case definition performance for SARS-CoV-2 surveillance; best practices for integrated surveillance from participating countries; interim standards for and current gaps in SARS-CoV-2 epidemiologic, laboratory and genomic sentinel surveillance; the Pandemic influenza severity assessment (PISA) and GISRS pandemic response plan; and the GISRS Plus strategy and roadmap. A full agenda is given in Annex 1.

Participants included national laboratory and epidemiology national focal points for influenza; experts from WHO Collaborating Centers and other laboratories of GISRS; international experts in surveillance of influenza, SARS-CoV-2 and other respiratory viruses; global and regional partners; and other interested bodies. A list of participants and their affiliations is provided in Annex 2.

Impact of the COVID-19 pandemic on influenza sentinel surveillance

The pandemic has caused disruptions to many elements of influenza surveillance systems, especially at the start of the pandemic. Surveillance was restarted integrating SARS-CoV-2 into influenza surveillance. Significant progress has been made by all countries taking part in integrated surveillance, including uploading data in a timely manner to FluNet and with at least 79% of GISRS laboratories having submitted data to the Global Initiative on Sharing All Influenza Data (GISAID).

The need for integrated respiratory sentinel surveillance

Meeting participants shared information on best practices for integrated influenza and SARS-CoV-2 surveillance, recognizing that these can be used to assist countries to overcome challenges in establishing and sustaining effective integrated surveillance. It was noted that there is increased national interest in respiratory surveillance at this time and an opportunity to work with new partners to build a resilient and effective surveillance system for the future. Participants agreed that we need to tackle the joint challenge of influenza [low circulation during the past year and thus low levels of immunity] and COVID-19 [continuing SARS-CoV-2 circulation and the threat of new variants] and to address co-circulation of these viruses; and we need to learn from the COVID-19 pandemic and to build integrated respiratory surveillance for the future that can rapidly integrate the surveillance of a new virus.

General lessons learned based on experience reported by participants include the need for:

- greater clarity on the definition of “integrated surveillance” and its core and expanded objectives [these could be collection of data for vaccine effectiveness studies]
support and practical guidance from WHO on:
- how to disaggregate sentinel and non-sentinel data from all surveillance data
- how to source samples from COVID-19 test centres (where necessary) so that representative samples meeting agreed case definitions are selected and essential meta-data are collected
- how to ensure a focus on higher quality data (that meet the agreed case definition and are therefore interpretable) is achieved
- what to do if core data are not available for the expanded sample set for samples meeting the agreed case definition
- clear recommendations on case definitions to be adopted, including addressing implications for comparisons with historical data
- guidance on actions required to report sentinel SARS-COV-2 results separately to FluNet.

The main principles that should guide adaptation of sentinel surveillance were the need for them to:
- be agile / adaptable - timely revisions to the system may be needed in future
- accommodate expansion – whilst maintaining feasibility, data quality and representativeness in a way that is sustainable
- maximize representativeness – essential for data extrapolation more widely beyond the surveillance population.
- facilitate future digitalisation – to promote real time access to data for decision making and timely intervention and to facilitate data management and data sharing; with the understanding that this would require detailed system specification and preparation [with in depth planning and piloting] and new electronic systems accessible to all stakeholders.

Integrated surveillance guidelines

It was noted that the systematic review of published studies and surveillance data from the 7 countries studies assessing ILI and SARI in different age groups against laboratory confirmed SARS-CoV-2 infection supported the recommendations that countries could continue to use ILI and SARI for influenza and SARS-CoV-2 surveillance and collect essential metadata. It was noted that countries with high testing capacities can continue with an ARI case definition.

Suggested revisions to the guidance document included:

A. Epidemiology

- ARI case definition to be recommended for case detection
- specification of a core minimum data set, aligned with core objectives
- more background on the rationale for 50-150 specimens / week
  - 50 per week is the minimum number per National Influenza Centre (NIC) to achieve core objectives
  - 150 per week is the ideal number per NIC, where possible
- additional specimens needed to achieve additional objectives
• more detail on sourcing of specimens from non-sentinel sites or SARS-CoV-2 testing laboratories needed
• recommendation to operate year-round surveillance in temperate climates to determine seasonality post-pandemic.

It was noted that the **use of non-sentinel systems will require attention** to:

• ensuring cases meet a recognized WHO case definition
• need for country-specific algorithms for selecting SARS-CoV-2 test samples
• sending metadata together with samples to the laboratory
• identifying data as from a sentinel or non-sentinel site
• support for consumables and for transport and other additional logistics
• need for guidelines / new authorisations for sharing samples with NICs
• need for staff feedback on problems to identify and solve problems
• staff training needs and human resources, with care not to over-burden staff
• consideration of what needs to be put in place to ensure sustainability.

It was noted that NICs may be able to secure additional samples from non-sentinel sites or COVID-19 testing laboratories to meet sample size requirements. However, priority should be given to samples from patients with symptoms consistent with the ILI/SARI/ARI case definitions, who represent the wider population seeking healthcare. Data recording and reporting should distinguish sentinel from non-sentinel sites, and data should be reported appropriately to global and/or regional platforms.

### B. Laboratory

The meeting highlighted the need for clear guidance on sample size for testing and sequencing and on how to maintain representativeness of samples [if testing more than 150 such as during epidemics]. It was noted that there was a need for robust genomic surveillance to assess the impact of emerging variants; and for contingency plans for accumulating mutations in terms of re-manufacture, re-qualification, and quality control processes. It was suggested that the use of variant-specific polymerase chain reaction (PCR) for surveillance may be useful when there is no dominant variant [but is not useful for clinical decision-making]. It was considered important to:

• maximize representativeness, timeliness, continuity and quality [rather than quantity]
• upload sequences to GISAID or other publicly accessible databases weekly or fortnightly, together with essential minimum metadata including sampling strategy variable
• develop more concrete guidance on the use of sequencing, including guidance on sample size
• link the guidance on technical quality of sequencing to WHO COVID-19 laboratory network guidance on sequencing
• build a sustainable laboratory infrastructure for different viruses as an essential element of GISRS Plus.
GISRS Plus

GISRS has gained extensive experience over many years and is a secure platform and strong foundation from which to build integrated surveillance. GISRS Plus adds in other respiratory viruses with epidemic and pandemic potential; integrates laboratory and epidemiological capabilities and built upon the success of the existing GISRS infrastructure [whilst not creating parallel systems]. It was agreed that there is a need to prepare GISRS Plus to meet both influenza and SARS-CoV-2 future surveillance needs, and it was noted that there is the potential for GISRS Plus to track future COVID-19 activity globally. Consequently, there is a need to prepare GISRS to meet future SARS-CoV-2 (as well as influenza) needs.

It was proposed that the core objectives of GISRS integrated surveillance should be achievable with ILI and SARI case definitions and proposed sample sizes and include:

- signalling the start and end of influenza and SARS-CoV-2 epidemic periods and describing the seasonality
- establishing baseline levels of activity for illness and severe disease [to evaluate the impact and severity of each epidemic period and of future pandemic events]
- identifying locally circulating virus types and subtypes and their relationship to global and regional patterns
- providing candidate viruses for vaccine production.

Additional objectives included identifying high risk groups; understanding the relationship between virus strains and disease severity; generating data for focused studies on health and economic burden and to help decision-makers prioritize resources and plan public health interventions; providing a platform for vaccine effectiveness studies; monitoring antiviral sensitivity; describing the antigenic character and genetic makeup of circulating viruses; and detecting unusual and unexpected events or clusters that may herald a change in virus characteristics. It was noted that in deciding whether to adopt additional (non-core) objectives, sustainability should be carefully considered.

GISRS Plus roadmap

A broader respiratory pathogen preparedness and response approach aligns with the vision in the Global Influenza Strategy 2019-2030, and GISRS will continue to be the backbone for pandemic preparedness and response. Whilst the development of GISRS Plus is a logical next step, this needs to be done in a measured and scientific manner, working together with countries and with resources made available to countries. It was agreed that GISRS Plus gives the opportunity to expand cooperation and should help ensure sustainability. It was noted that for countries that cannot add new pathogens, consideration should be given to how support can be given to help them engage in GISRS Plus. It was recommended that, based on experience in WHO PISA, a core set of parameters for seasonal and pandemic situations; more emphasis on health care capacity measurements; more work on the threshold setting in pandemic situations; and inclusion of dynamic parameters are all needed.

The GISRS Pandemic Response Plan [PRPi] has been developed to describe the overall GISRS operational response to an influenza pandemic; synergize national and wider GISRS
responses; guide preparedness and readiness of all GISRS partners; and serve as a foundation for future development of GISRS PRPx for other viruses.

Conclusions and next steps

A summary list of priority actions included:

- finalization of revised guidance and a compendium of best practices as soon as possible
- definition of the objectives and development of operational plans for integrated surveillance at the country level, following the revised guidance and with WHO support [in providing training, logistics support and additional guidance]
- review the use of and secure supplies of multiplex PCR kits and ancillary reagents
- review laboratory procedures, focusing on those laboratories with a reduced performance in the external quality assessment project (EQAP) 2021 and with support from WHO on reagents [jointly with International Reagent Resource], tailored training, on-site problem-solving on virus detection; and guidance and support to achieve a sustainable laboratory infrastructure
- review of the timeliness and completeness of current reporting of data in regional platforms or directly to FluNet and FluID and of subsequent analysis and feedback to sentinel sites and relevant stakeholders with WHO support in training, developing online training modules and one-on-one mentoring; and communicating results
- working at the country level to achieve representative, systematically sampled viruses from sentinel surveillance systems for sequencing and with uploading of sequence and meta data according to the GISRS guidance; with support from this WHO, which will monitor the development of sequencing capacity in GISRS and the completeness and timeliness of uploaded genetic sequence data; continue to support sequencing capacity building in GISRS (including with reagents, logistics arrangements and sequencing and bioinformatics collaborations with GISAID and other agencies); develop and implement strategic plans and guidance for GISRS genomic surveillance; and help build sustainable capacity at national, regional and global levels.
- completion of a landscape analysis of GISRS capacities.

The meeting closed with a reminder for countries to be vigilant about influenza threats and to get ready for situations of co-circulating of influenza and SARS-CoV-2 viruses; to be alert to unusual clusters of non-COVID-19 respiratory cases; to raise awareness among policy makers of the threat of influenza; and to resume influenza surveillance and monitoring activities, including the reporting of PISA indicators.

References

2nd WHO Global Consultation on the Integrated Sentinel Surveillance of Influenza and SARS-CoV-2 and the Development of GISRS Plus
(virtual meeting)

FINAL AGENDA
Chair: Dr. Mahmudur Rahman
(Meeting room will open at 10:45AM CET each day)

Day 1: 12 October 2021, 11h00 – 14h15 CET

11:00 – 11:15 Opening
Objectives, expected outcomes
Disclosure of interests declared by experts
Selection of chair and co-chairs
Sylvie Briand
Wenqing Zhang

11:15 – 11:20 Housekeeping rules
Aspen Hammond

Session 1: Best practice models of integrated surveillance of influenza and SARS-CoV-2

Siddhi Hirve

11:35 – 11:55 Best practices of end-to-end integration of influenza and SARS-CoV-2 – key considerations
Durga Kulkarni
Madhurima Nundy

11:55 – 12:05 Health break – instructions for group discussions

12:05 – 13:30 Breakout group discussions:
From field experiences to best practice models of integrated surveillance of influenza and SARS-CoV-2
Group leads:
Room #1 - Angel Rodriguez
Room #2 - Francis Inbanathan
Room #3 – Karen Nahapetyan
Room #4 - Amal Barakat

13:30 – 14:15 Panel discussion:
what surveillance practices worked and in what context?
Moderator: Belinda Herring
14:15  Close of day 1
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:05</td>
<td>Recap of day 1</td>
<td>Mahmudur Rahman</td>
</tr>
<tr>
<td>11:35 – 11:50</td>
<td>Overview – Objectives of GISRS integrated surveillance - Panel discussion</td>
<td>Christina Bancej</td>
</tr>
<tr>
<td>11:50 – 12:00</td>
<td>Health break / Break into parallel sessions</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:40</td>
<td>Sentinel systems – revisions in the guidance - Panel discussion</td>
<td>Silvia Bino&lt;br&gt;Moderator: Pushpa Wijesinghe&lt;br&gt;Panelists: Carla Voto, Ivy Asante, Mayan Lumandas, Silvia Bino</td>
</tr>
<tr>
<td>12:40 – 13:20</td>
<td>Sourcing specimens - Panel discussion</td>
<td>Sibongile Walaza&lt;br&gt;Moderator: Andrea Vicari&lt;br&gt;Panelists: Talat Mokhtari, Flavia Riccardo, Sikuru Badaru, Chinthana Perera</td>
</tr>
<tr>
<td>13:20</td>
<td>Re-group to plenary</td>
<td></td>
</tr>
<tr>
<td>13:35 – 14:00</td>
<td>Panel Discussion: Sentinel surveillance to inform public health decisions</td>
<td>Moderator: Julia Fitzner&lt;br&gt;Panelists: Jean-Michel Heraud, Varsha Potdar, Silke Buda, Jim McMenamin</td>
</tr>
<tr>
<td>14:00</td>
<td>Close of day 2</td>
<td></td>
</tr>
</tbody>
</table>
Day 3: 14 October 2021, 11h00 – 14h00 CET

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:05</td>
<td>Chair’s remarks</td>
<td>Mahmudur Rahman</td>
</tr>
<tr>
<td>11:05 – 11:30</td>
<td>Summarizing the discussions and outputs from the surveillance session of day 2</td>
<td>Harry Campbell</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:30 – 11:55</td>
<td>Summarizing the discussions and outputs from the laboratory session of day 2</td>
<td>Marie-jo Medina</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:55 – 12:05</td>
<td>Health break</td>
<td></td>
</tr>
<tr>
<td>12:05 – 12:45</td>
<td>GISRS Plus roadmap</td>
<td>Ann Moen</td>
</tr>
<tr>
<td></td>
<td>Panel discussion</td>
<td>Moderator: Ann Moen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists: Sonam Wangchuk, Stefano Tempia, Erik Karlsson, John McCauley, Sylvie van der Werf</td>
</tr>
<tr>
<td>12:45 – 13:05</td>
<td>WHO Pandemic Influenza Severity Assessment</td>
<td>Holly Sadler</td>
</tr>
<tr>
<td></td>
<td>an update</td>
<td>Kaat Vandemaele</td>
</tr>
<tr>
<td>13:05 – 13:25</td>
<td>GISRS Pandemic Response Plan development</td>
<td>Xiyan Xu</td>
</tr>
<tr>
<td></td>
<td>an update</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:45 – 13:55</td>
<td>Chair summary remarks</td>
<td>Mahmudur Rahman</td>
</tr>
<tr>
<td>13:55 – 14:00</td>
<td>Closing remarks</td>
<td>WHO</td>
</tr>
<tr>
<td>14:00</td>
<td>Close of consultation</td>
<td></td>
</tr>
</tbody>
</table>
Annex 2. List of participants

Jyoti Acharya
National Public Health Laboratory, Nepal

Abdul Ahad
National Institute of Health, Pakistan

Annette Alafaci
Murdoch Children’s Research Institute, Australia

Mona Albeaini
Rafic Hariri University Hospital, Lebanon

Mohamed Ali
Laboratory Medicine and Pathology, Qatar

Naema Al-Mawlawi
Laboratory Medicine and Pathology, Qatar

Vina Lea Arguelles
Research Institute for Tropical Medicine, Philippines

Ammar Aziz
Royal Melbourne Hospital, Australia

Gunter Bach
GISAID, Germany

Christina Bancej
Public Health Agency, Canada

Bakamutumaho Barnabas
Uganda Virus Research Institute, Uganda

Ian Barr
Victorian Infectious Diseases Reference Laboratory, Australia

Elsa Baumeister
INEI-ANLIS "Carlos G. Malbrán", Argentina

Sumit Bhardwaj
ICMR-NIV Pune, India

Jinal Bhiman
National Institute for Communicable Diseases, South Africa

Shabana Bi
Public Health England, United Kingdom

David Blazes
Bill & Melinda Gates Foundation, USA

Peter Bogner
GISAID, Germany

Louis Bont
UMC Utrecht, Netherland

Eeva Broberg
GISAID, Sweden

Shobha Broor
SGT Medical College, Hospital & Research Institute, India

Silke Buda
Robert Koch Institute, Germany

Braulia Caetano
FIOCRUZ, Brazil

Wei Cai
Robert Koch Institute, Germany

Harry Campbell
The University of Edinburgh, United Kingdom

Lok Bandhu Chaudhary
National Public Health Laboratory, Nepal

Marcela Santos Correia da Costa
Saúde Brasil, Brazil

Felipe Cotrim de Carvalho
Saúde Brasil, Brazil

Daouda Coulibaly
Institut national d’Hygiène publique, Côte d’Ivoire

Nigel Crawford
SAEFVIC, Australia
Catherine Dacasin  
Research Institute for Tropical Medicine, Philippines

Ndongo Dia  
National Influenza Centre, Senegal

Lien Anh Ha Do  
Murdoch Children’s Research Institute, Australia

Audrey Dubot-Pérès  
UVE, France

Suzanne Elgohari  
Public Health England, United Kingdom

Manal Morcos Fahim  
Ministry of Health and Population, Egypt

Rodrigo Fasce  
National Influenza Centre, Chile

Anne von Gottberg  
National Institute for Communicable Diseases, South Africa

Celine Gurry  
GISAID, Germany

Aron Hall  
Centers for Disease Control and Prevention, USA

Jean-Michel Heraud  
Institut Pasteur, Madagascar

Runa Jha  
National Public Health Laboratory, Nepal

Erik Karlsson  
Institut Pasteur, Cambodia

Raphael Tze Chuen Lee  
A-Star-Education, Singapore

Xiaoyan Lu  
Centers for Disease Control and Prevention, USA

Adam MacNeil  
Centers for Disease Control and Prevention, USA

Yi-Mo Deng  
Victorian Infectious Diseases Reference Laboratory, Australia

Boly Diop  
Ministry of Health and Social Action, Senegal

Xiaomin Dong  
Victorian Infectious Diseases Reference Laboratory, Australia

Philippe Dussart  
National Influenza Centre, Madagascar

Joanna Ellis  
Public Health England, United Kingdom

Amary Fall  
Institut Pasteur, Senegal

Walquiria Aparecida Ferreira de Almeida  
Saúde Brasil, Brazil

Stephanie Goya  
Ricardo Gutiérrez Children’s Hospital, Argentina

Walter Haas  
Robert Koch Institute, Germany

Suthida Muangnoicharoen Hearn  
Ministry of Health, Thailand

Deborah Higgins  
PATH, USA

Herve Kadjo  
Institut Pasteur, Côte d'Ivoire

Naomi Komadina  
Victorian Infectious Diseases Reference Laboratory, Australia

Chowdhary Lokbandhu  
National Public Health Laboratory, Nepal

Mayan Lumandas  
Research Institute for Tropical Medicine, Philippines

Sebastian Maurer-Stroh  
GISAID, Singapore
Meredith McMorrow  
Centers for Disease Control and Prevention, USA

Ali Ben Hadj Kacem Mohamed  
National Influenza Centre, Qatar

Jocelyn Moyes  
National Institute for Communicable Diseases, South Africa

Kim Mulholland  
Murdoch Children’s Research Institute, Australia

Harish Nair  
The University of Edinburgh, United Kingdom

Joyce Namulondo  
Virus Research Institute, Uganda

Anderson Ngattia  
Institut National d’Hygiène Publique, Côte d’Ivoire

Rahombanjanahary Norosoa  
Institut Pasteur, Madagascar

Maria Fernanda Olivares  
Ministry of Health, Chile

John Paget  
NIVEL, Netherlands

Pasi Penttinen  
European Centre for Disease Prevention and Control, Sweden

Maria Pisareva  
Research Institute of Influenza, Russian Federation

Joelintoshina H. Rabarison  
Institut Pasteur, Madagascar

Antso H. Raherinandrasana  
Ministère de la Santé Publique, Madagascar

Tsiry H. Randriambolamanantsoa  
Institut Pasteur, Madagascar

Paola Resende  
FIOCRUZ, Brazil

Thulisa Mkhencele  
National Institute for Communicable Diseases, South Africa

Jonjee Morin  
Research Institute for Tropical Medicine, Philippines

Gordon Mpamize  
Joint Clinical Research Centre, Uganda

Amel Hasanin Naguib  
National Influenza Centre, Egypt

Hala Abou Naja  
Ministry of Health, Lebanon

TS. Naranzul  
National Center for Communicable Diseases, Mongolia

Neuza Nguenha  
National Influenza Centre, Mozambique

Plailuk Okada  
National Influenza Centre, Thailand

Hicham Oumzil  
Ministry of Health, Morocco

Mirela Pale  
Instituto Nacional de Saúde, Mozambique

Teresa Peret  
Centers for Disease Control and Prevention, USA

Varsha Potdar  
National Influenza Centre, India

Sonia M Raboni  
Universidade Federal do Paraná, Brazil

Mohannad Ramadan  
School of Medicine, Jordan

Norosoa Razanajatovo  
Institut Pasteur, Madagascar

Ahmed Rguig  
Ministry of Health, Morocco
Sanjiv Rughooputh  
Public Health England, United Kingdom

Wedad Saleem  
Laboratory Medicine and Pathology, Qatar

Marilda Siqueira  
FIOCRUZ, Brazil

Peter George Smith  
London School of Hygiene & Tropical Medicine, United Kingdom

Padmini Srikantiah  
Bill & Melinda Gates Foundation, USA

Annabelle Sucuano  
Research Institute for Tropical Medicine, Philippines

Sana Tamim  
National Institute of Health, Pakistan

Almiro Tivane  
National Influenza Centre, Mozambique

Sylvie van der Werf  
Institut Pasteur, France

Everardo Vega  
Centers for Disease Control and Prevention, USA

Marie Vernet  
Institut Pasteur, Central African Republic

Carla Voto  
Ministry of Health, Argentina

Conall Watson  
Public Health England, United Kingdom

Daniel Weinberger  
Yale School of Public Health, USA

Thomas William  
University of Edinburgh, United Kingdom

Oiythip Yasopa  
Ministry of Health, Thailand

Mara Russo  
Saúde Brasil, Brazil

Eric Simoes  
Center for Global Health, Colorado, USA

Whitney Skowronski  
CDC Foundation, USA

Elizaveta Smorodintseva  
Research Institute of Influenza, Russian Federation

Koshal Chnadra Subedi  
Ministry of Health and Population, Nepal

Tiina Talts  
Public Health England, United Kingdom

Miriam Terezinha  
Saúde Brasil, Brazil

Mend Tsogt  
National Center for Communicable Diseases, Mongolia

Miquelina Chicanequisso Vaz  
Ministry of Health, Mozambique

Marietjie Venter  
National Institute for Communicable Diseases, South Africa

Mariana Viegas  
CONICET, Argentina

Niteen Wairagkar  
Independent consultant, USA

Saleem Wedad  
National Influenza Centre, Qatar

Brett Whitaker  
Centers for Disease Control and Prevention, USA

Mahmoud Yacoub  
CDD, Jordan

Maria Zambon  
Public Health England, United Kingdom

Theodor Ziegler  
Independent consultant, Finland
<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abdinasir Abubakar</td>
<td>EM/RGO/WHE/IHM</td>
</tr>
<tr>
<td>2</td>
<td>Lubna Al Ariqi</td>
<td>EM/RGO/WHE/IHP</td>
</tr>
<tr>
<td>3</td>
<td>Lora Alsawalha</td>
<td>EM/ACO/JOR</td>
</tr>
<tr>
<td>4</td>
<td>Moubadda Assi</td>
<td>EM/ACO/LEB</td>
</tr>
<tr>
<td>5</td>
<td>Amal Barakat</td>
<td>EM/RGO/WHE/IHP</td>
</tr>
<tr>
<td>6</td>
<td>Cyril Barbezange</td>
<td>EU/RGO/WHE/IHM</td>
</tr>
<tr>
<td>7</td>
<td>Uzma Bashir</td>
<td>EM/ACO/PAK</td>
</tr>
<tr>
<td>8</td>
<td>Nirajan Bhusal</td>
<td>SE/ACO/NEP</td>
</tr>
<tr>
<td>9</td>
<td>Sylvie Briand</td>
<td>HQ/WHE/IHM</td>
</tr>
<tr>
<td>10</td>
<td>Rowena Capistrano</td>
<td>WP/ACO/PHL</td>
</tr>
<tr>
<td>11</td>
<td>Adam Cohen</td>
<td>HQ/FWC/IVB/EPI</td>
</tr>
<tr>
<td>12</td>
<td>Paula Couto</td>
<td>AM/PAHO</td>
</tr>
<tr>
<td>13</td>
<td>Vanessa Cozza</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>14</td>
<td>Hassene Debbiche</td>
<td>HQ/BOS/WCS</td>
</tr>
<tr>
<td>15</td>
<td>Hien Doan</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>16</td>
<td>Daniel Feikin</td>
<td>HQ/FWC/IVB</td>
</tr>
<tr>
<td>17</td>
<td>Julia Fitzner</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>18</td>
<td>Martin Friede</td>
<td>HQ/FWC/IVB/IVR</td>
</tr>
<tr>
<td>19</td>
<td>Elizabeth Frodeman</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>20</td>
<td>Christian Fuster</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>21</td>
<td>Arunkumar Govinda</td>
<td>SE/ACO/NEP</td>
</tr>
<tr>
<td>22</td>
<td>Aspen Hammond</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>23</td>
<td>Belinda Herring</td>
<td>AF/RGO/WHE/IHM</td>
</tr>
<tr>
<td>24</td>
<td>Siddhivinayak Hirve</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>25</td>
<td>Francis Y. Inbanathan</td>
<td>SE/RGO/WHE/IHM</td>
</tr>
<tr>
<td>26</td>
<td>Sandra Jackson</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>27</td>
<td>Jorge Jara</td>
<td>AM/PAHO</td>
</tr>
<tr>
<td>28</td>
<td>Priya Jha</td>
<td>SE/ACO/NEP</td>
</tr>
<tr>
<td>29</td>
<td>Juliana Leite</td>
<td>AM/PAHO</td>
</tr>
<tr>
<td>30</td>
<td>Maja Lievre</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>31</td>
<td>Bikram Maharjan</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>32</td>
<td>Awandha Mamahit</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>33</td>
<td>Marie-jo Medina</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>34</td>
<td>Ann Moen</td>
<td>HQ/WHE/IHM/IPR</td>
</tr>
<tr>
<td>35</td>
<td>Karen Nahapetyan</td>
<td>WP/RGO/WHE/CPI</td>
</tr>
<tr>
<td>36</td>
<td>Richard Pebody</td>
<td>EU/RGO/WHE/IHM</td>
</tr>
<tr>
<td>37</td>
<td>Dmitriy Pereyaslove</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>38</td>
<td>Angel Rodriguez</td>
<td>AM/PAHO</td>
</tr>
<tr>
<td>39</td>
<td>Magdi Samaan</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>40</td>
<td>Saugat Shrestha</td>
<td>SE/ACO/NEP</td>
</tr>
<tr>
<td>41</td>
<td>Erin Sparrow</td>
<td>HQ/UHL/IVB/PDR</td>
</tr>
<tr>
<td>42</td>
<td>Katelijn Vandemaele</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
<tr>
<td>43</td>
<td>Andrea S. Vicari</td>
<td>AM/PAHO</td>
</tr>
<tr>
<td>44</td>
<td>Pushpa R. Wijesinghe</td>
<td>SE/RGO/WHE/IHM</td>
</tr>
<tr>
<td>45</td>
<td>Wenqing Zhang</td>
<td>HQ/WHE/IHM/GIP</td>
</tr>
</tbody>
</table>
Annex 3. Declarations of interest

The WHO consultation on integrated sentinel surveillance of influenza and SARS-CoV-2 and the development of Global Influenza Surveillance and Response System Plus was held on 12–14 October 2021 as a virtual meeting.

In accordance with WHO policy, all WHO external participants completed the WHO form for Declaration of Interests for WHO experts before being invited to the consultation. At the start of the consultation, the interests declared were disclosed to all participants.

The interests declared by the participants were reviewed by WHO and determined not to present a conflict of interest with the objectives of the WHO consultation.